Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CGEM logo

Cullinan Oncology LLC (CGEM)CGEM

Upturn stock ratingUpturn stock rating
Cullinan Oncology LLC
$15.92
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/04/2024: CGEM (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 0.32%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 35
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/04/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 0.32%
Avg. Invested days: 35
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/04/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.01B USD
Price to earnings Ratio -
1Y Target Price 32.38
Dividends yield (FY) -
Basic EPS (TTM) -3.06
Volume (30-day avg) 409330
Beta -0.12
52 Weeks Range 7.64 - 30.19
Updated Date 11/12/2024
Company Size Small-Cap Stock
Market Capitalization 1.01B USD
Price to earnings Ratio -
1Y Target Price 32.38
Dividends yield (FY) -
Basic EPS (TTM) -3.06
Volume (30-day avg) 409330
Beta -0.12
52 Weeks Range 7.64 - 30.19
Updated Date 11/12/2024

Earnings Date

Report Date 2024-11-06
When BeforeMarket
Estimate -0.81
Actual -0.69
Report Date 2024-11-06
When BeforeMarket
Estimate -0.81
Actual -0.69

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -20.4%
Return on Equity (TTM) -26.53%

Valuation

Trailing PE -
Forward PE 6.3
Enterprise Value 345829531
Price to Sales(TTM) 26.88
Enterprise Value to Revenue 11.55
Enterprise Value to EBITDA -1.46
Shares Outstanding 58227600
Shares Floating 38537932
Percent Insiders 4.5
Percent Institutions 114.88
Trailing PE -
Forward PE 6.3
Enterprise Value 345829531
Price to Sales(TTM) 26.88
Enterprise Value to Revenue 11.55
Enterprise Value to EBITDA -1.46
Shares Outstanding 58227600
Shares Floating 38537932
Percent Insiders 4.5
Percent Institutions 114.88

Analyst Ratings

Rating 4.8
Target Price 24.6
Buy 2
Strong Buy 8
Hold -
Sell -
Strong Sell -
Rating 4.8
Target Price 24.6
Buy 2
Strong Buy 8
Hold -
Sell -
Strong Sell -

AI Summarization

Cullinan Oncology LLC: A Comprehensive Overview

Company Profile:

Detailed History and Background: Founded in 2019 and headquartered in Lexington, Massachusetts, Cullinan Oncology LLC is a privately held clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with hematologic malignancies and solid tumors. The company leverages its deep understanding of protein degradation and innate immunity to design and develop therapies that address unmet medical needs.

Core Business Areas: Cullinan Oncology focuses on two core areas:

  • Protein Degradation: The company utilizes targeted protein degradation (TPD) platforms to develop small-molecule therapies that selectively degrade disease-causing proteins.
  • Innate Immunity: Cullinan leverages its expertise in innate immunity to develop therapies that activate the body's natural defenses to fight cancer.

Leadership and Corporate Structure: Cullinan Oncology is led by a team of experienced executives in the pharmaceutical industry. William (Bill) G. Rice, M.D., serves as President and Chief Executive Officer. The leadership team includes experts in drug discovery, development, and commercialization.

Top Products and Market Share:

Top Products: Cullinan Oncology has several promising programs in its pipeline, including:

  • CLN-081: A first-in-class TPD degrader of the transcription factor GATA3, which is overexpressed in several hematologic malignancies.
  • CLN-619: A small-molecule TPD degrader of Bruton's tyrosine kinase (BTK), a validated target in B-cell malignancies.
  • CLN-515: A novel STING agonist designed to stimulate the body's innate immune response to fight cancer.

Market Share: As a privately held company, Cullinan Oncology does not publicly disclose its market share. However, the company's innovative approach to protein degradation and innate immunity has positioned it as a leader in these emerging therapeutic areas.

Product Performance and Market Reception: Cullinan Oncology's programs are in preclinical and early clinical development stages. The company has presented promising preclinical data for CLN-081 and CLN-515, which have received positive feedback from the scientific community.

Total Addressable Market:

The global market for cancer therapeutics is estimated to reach USD 164.37 billion by 2028, growing at a CAGR of 19.7%. Cullinan Oncology's focus on hematologic malignancies and solid tumors addresses a significant portion of this market.

Financial Performance:

As a privately held company, Cullinan Oncology does not disclose its financial performance publicly. However, the company has secured significant funding rounds from leading investors, highlighting its potential in the oncology field.

Dividends and Shareholder Returns:

As a privately held company, Cullinan Oncology does not currently pay dividends.

Growth Trajectory:

Cullinan Oncology has demonstrated strong growth potential with its innovative approach to cancer therapy. The company is actively advancing its pipeline through clinical development and expanding its research and development capabilities.

Market Dynamics:

The oncology market is dynamic and rapidly evolving. Key trends include:

  • Precision Medicine: Developing targeted therapies based on the genetic characteristics of tumors.
  • Immunotherapy: Harnessing the body's immune system to fight cancer.
  • Emerging Technologies: Utilizing artificial intelligence and other advanced technologies to accelerate drug discovery and development.

Cullinan Oncology is well-positioned to capitalize on these trends with its focus on protein degradation, innate immunity, and targeted therapies.

Competitors:

Cullinan Oncology faces competition from several pharmaceutical companies developing therapies for hematologic malignancies and solid tumors. Key competitors include:

  • Argenx: Stock symbol (ARGX)
  • Amgen: Stock symbol (AMGN)
  • Bristol Myers Squibb: Stock symbol (BMY)
  • Pfizer: Stock symbol (PFE)

Competitive Advantages and Disadvantages: Cullinan Oncology's competitive advantages include its proprietary protein degradation platforms, unique therapeutic targets, and experienced leadership team. Potential disadvantages include the early stage of development of its pipeline and the competitive landscape in the oncology market.

Potential Challenges and Opportunities:

Key Challenges: Cullinan Oncology faces challenges such as navigating the complex regulatory landscape, demonstrating the safety and efficacy of its therapies in clinical trials, and achieving commercial success in a competitive market.

Potential Opportunities: Opportunities include expanding its pipeline through internal research and development, strategic partnerships, licensing deals, and acquisitions. Additionally, the company can leverage its expertise in protein degradation and innate immunity to develop novel therapies addressing unmet medical needs.

Recent Acquisitions (last 3 years):

Cullinan Oncology has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

An AI-based fundamental rating for Cullinan Oncology LLC is not available, as the company is privately held and does not publicly disclose its financial information.

Sources and Disclaimers:

This overview is based on publicly available information from sources such as Cullinan Oncology's website, press releases, and industry reports.

This information is for general knowledge and educational purposes only, and does not constitute investment advice. Please consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Cullinan Oncology LLC

Exchange NASDAQ Headquaters Cambridge, MA, United States
IPO Launch date 2021-01-08 President, CEO & Director Mr. Nadim Ahmed
Sector Healthcare Website https://cullinantherapeutics.com
Industry Biotechnology Full time employees 85
Headquaters Cambridge, MA, United States
President, CEO & Director Mr. Nadim Ahmed
Website https://cullinantherapeutics.com
Website https://cullinantherapeutics.com
Full time employees 85

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​